Skip to main content

Advertisement

Table 1 Baseline patient characteristics by treatment

From: Cosmetic outcome as rated by patients, doctors, nurses and BCCT.core software assessed over 5 years in a subset of patients in the TARGIT-A Trial

Patient, treatment and tumour characteristics TARGIT-IORT EBRT
Number of patients (% of total) 60 (48%) 66 (52%)
Age (mean years +/− SD)
Range
63 (+/−  8.2)
50–83
62 (+/−  7.4)
50–80
Randomised prepathology (before WLE)
Randomised postpathology (after WLE)
4 (7%)
56 (93%)
14 (21%)
52 (79%)
Baseline assessments prior to any surgery N (% of treatment group) 2 (3%) 12 (18%)
Baseline BMI (mean score kg/m 2 +/− SD)
Baseline BMI Group a (% pf treatment group)
29 (+/− 5.5) 30 (+/−  5.9)
1 – Underweight (< 18.5) 0% 0%
2 – Normal (18.5–24.99) 30% 16%
3 – Overweight (25–29.99) 30% 50%
4 – Obese (30+) 40% 34%
Tumour Size (mm mean ± SD)
Tumour Size Group, % of treatment group
10 (+/− 4.2) 11 (+/− 5.0)
  < 11(mm) 62% 52%
11–20 (mm) 38% 46%
  > 21(mm) b 1.5%
Tumour Grade, n (% of treatment group)
1 37 (62%) 38 (57%)
2 23 (38%) 27 (41%)
3b 0 1 (1.5%)
Tumour Type, n (% of treatment group)
IDC
Mixed IDC/ILCb
59 (98%)
1 (1.7%)
64 (97%)
2 (3%)
Lesions, n (% of treatment group)
1 60 (100%) 65 (98%)
2b 0 1 (1.5%)
Extensive DCIS (> 25% of tumour + inside and out of tumour) b n (% of treatment group) 0 4 (6.3%)
Hormone receptor status, n (% of treatment group)
ER + ve 60 (100%) 64 (97%)
PR + ve 44 (73%) 52 (79%)
ER and PR –ve b 0 2 (3%)
Positive Nodes b , n (% of treatment group) 0 1 (1.5%) (1 node)
Largest Specimen Length (mean -mm +/− SD)
Range
89 (+/−  37.2)
25–205
89 (+/−  38.4)
40–267
Extent of Axillary Surgery, n (% of treatment group)
Nil 3 (5%) 2 (3%)
SLNBx 49 (82%) 55 (83%)
Clearance 8 (13%) 9 (14%)
Further Surgery Required, n (% of treatment group)
SLNBx 2 (3.3%) 2 (3%)
Margins 2 (3.3%) 7 (11%)
Revision of Scar 2 (3.3%) 0
Radiotherapy Dose Range (Gy) 16-33c 45–50.4
Fractions (range) 1 25 (25–28)
Boost Given (20Gy in 10 fractions), n (% of treatment group) N/A 11 (17%)
Supraclavicular Treatment, n (% of treatment group) N/A 1 (1.5%)
Chemotherapy given b (n, % of treatment group) 0 1 (1.5%)
Baseline Cosmesis Scores (% Excellent-Good), mean (± SD)
Patient Harris 85 (+/− 0.36) 82 (+/− 0.39)
Nurse Harris 93 (+/− 0.25) 92 (+/− 0.27)
Doctor Harris† 87 (+/−  0.35) 100 (+/−  0.0)
BCCT.Core 83 (+/−  0.38) 90 (0.31)
  1. Abbreviations: WLE: Wide Local Excision; BMI: body mass index; DCIS: ductal carcinoma in situ; EBRT = external beam radiation therapy; ER: estrogen receptor; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma; PR: progesterone receptor; SD: standard deviation; SLNBx: sentinel lymph node biopsy; TARGIT-IORT: targeted intraoperative radiation therapy
  2. aSee reference 28; b Factors relevant only to the prepathology stratification; cDose to surface of applicator; † Significantly different (p = 0.003)